BOSTON & MONTREAL, January 31, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

The Program Committee of the AUA has accepted the Theralase®'s abstract titled: ' Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive ...

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...

LOS ANGELES—On a typical weekday, lunch hour is bustling at Toscana Brentwood, a popular restaurant with the Hollywood elite where it isn’t uncommon to see Disney Chief Executive Bob Iger ...

BCG unresponsive non-muscle invasive bladder cancer (NMIBC) in the papillary indication: Anticipated supplemental biologics license application (BLA) submission in 2025 Alternative source of BCG in ...

When looking at acres burned, the Palisades and Eaton fires are small compared with other massive California fires. However, when you rank them by the number structures destroyed the recent fires ...